Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NWBO could jump as high as Celator, now a subsidiary of JAZZ Pharma.
https://www.google.com/amp/s/www.fool.com/amp/investing/2016/06/27/why-celator-pharmaceuticals-is-up-1610-in-2016.aspx
According to Yahoo Finance, Insider ownership is 30% and institutional is 42%. Tdameritrade has institutional @ 18%.
What is a data lock?
Usually, when it comes to pending news, short sellers will come in to get people to sell so they can gobble up those shares. This stock, like many others, have their ups and downs because of this manipulation.
What bad news?
$2 according to Zack's Research
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/ONCYF-FDA-Grants-Fast-Track-Authority/default.aspx
A partnership could boost it to that level, but I'm hoping for a
buyout.
All too often I've seen this stock played with. $3 no way. Pharma/Biotech are the most manipulated stocks. It would be a miracle if it reaches above $2.45.
Yes, I would like for it to go north, but these short sellers play their game with these stocks (especially biotech/pharma co's) and it will be in their court unless some crazy news comes out. I'm hoping for a major partnership or a total buyout.
Did you listen to the conference, and if so, are basing your figure on what you heard?
Is that your prediction for close tomorrow or runup next week?
BIG DAY x 2 >>> House vote on repeal and replace of un-Affordable Care Act and AH meeting. Slight pullback by short sellers. Noodle sentiment: Strong Buy!
I have to admit, I sold my shares yesterday before the close. I sold them before the discovery that the FDA approved Seroquel XR. I noticed the uptrend AH. I never bothered to look at the volume AH, just the name Impactrader and felt like this thing would be pumped and dumped. Perhaps, I'll come back after all the short sellers quit playing their games. Of course, it will be hard to judge when to get back in. This lawsuit could take a while or it could pop on some insane news story. For now, go ONCYF!
It appears to me that someone is not wanting this thing to go up much higher today. Before I finish this post the markets would have closed. I'm sure this person or group of people are trying to play the fear factor because of tomorrow's BIG DAY ( I think it's a big day). They might even try to take it lower (beyond today's high/close) tomorrow to get people to sell so they can buy it cheaper Friday morning. Who knows what tomorrow will bring. I'm hoping it soars past .70 on pure speculation and stays above that knowing tomorrow's BIG DAY is after hours. Friday should be interesting!!!
Google Finance will have numerous articles covering Oncolytics on the Toronto side that are recent. Just Google, "ONC Google Finance" and notice on the right dated articles that are new. For example, here is one that was posted two hours ago. For some reason you won't find up-to-date articles on the ONCYF side which can easily be put in on the top search engine once you've opened up the Google Finance page. I'm sure the reason is because it's a Canadian company. With that said, it's nice to see the high volumes on the Canadian side. I sold my shares of IPCI (Intellipharmaceutics) because I wanted to go "ALL In" with ONCYF. IPCI on the TSX doesn't have anything close to the volumes on the Nasdaq side, and it's a Canadian company too.
https://6milestandard.com/volume-moving-the-tape-for-oncolytics-biotech-inc-onc-to/59341/
Fully diluted into 2018 on page 27. Major events coming soon.
Oncolytics (TSX:ONC) up nicely in Canada.
>>> 0.870 +0.110 (14.47%)
https://www.google.com/finance?cid=675210
Did you read my other post about their meeting on the 4th? We should know the details I hope about their future (near term) plans? Agree?
Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders
"CALGARY, April 27, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (ONC.TO) (ONCYF) announced today that its 2017 Annual Meeting of Shareholders will be held on Thursday, May 4th, 2017 at 4:00 pm ET (2:00 pm MT) at the Toronto Region Board of Trade located at First Canadian Place, Suite 350, 77 Adelaide Street West, Toronto, Ontario.
Following the business portion of the meeting, Dr. Matt Coffey, President and CEO of Oncolytics, will discuss recent progress in the development of REOLYSIN®, including recent randomized phase 2 metastatic breast cancer results as well as the detailed clinical development plan and specific initial registration pathway for REOLYSIN.
A live audio webcast of Dr. Coffey's presentation will begin at approximately 4:15 pm ET (2:15 pm MT) and be available at http://event.on24.com/r.htm?e=1415093&s=1&k=1D9EC98BC2D829CD19D1A85F7769DEAC and on the company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website."
https://finance.yahoo.com/news/oncolytics-biotech-inc-announces-details-110000855.html
After May 4th we should know whether it rises exponentially or not.
Let's hope this gets back to where it was a couple weeks ago and then some - i.e. over $1.00!!!!!!!!!!!!!!!!
Looks like someone or a group of people want this to remain below $2.20 today, and perhaps tomorrow and the next day. Can't see it staying above $2.25 that's for sure. I could be wrong.
Getting around that time for Impact to show up and buy 10,000 or so, and then...well, we know the story.
Some of the same points found here can be found on Drugchatter, except that they're abbreviated.
http://www.drugchatter.com/ticker/IPCI
I'm sure I know the answer. Do you think IPCI can muster a $3 range and stay there in the coming weeks?
With all those numbers I copied and pasted, the only way to see it clearly is on a regular computer screen. On the phone, it is hard to see where they begin and end.
Price action before and after the Oct, 11, 2016 "Exclusive and Commercial Supply Agreement with Mallinckrodt.
Date Open High Low Close Adj Cl Vol.
Oct 26, 2016 3.00 3.00 2.81 2.90 2.90 198,600
Oct 25, 2016 3.05 3.07 2.96 2.98 2.98 168,900
Oct 24, 2016 3.16 3.20 2.96 3.05 3.05 579,700
Oct 21, 2016 3.01 3.19 2.97 3.15 3.15 925,900
Oct 20, 2016 2.81 3.02 2.79 3.01 3.01 531,900
Oct 19, 2016 2.70 2.96 2.61 2.86 2.86 733,900
Oct 18, 2016 2.80 2.80 2.64 2.67 2.67 336,500
Oct 17, 2016 2.88 2.88 2.70 2.75 2.75 355,100
Oct 14, 2016 2.99 2.99 2.73 2.86 2.86 675,600
Oct 13, 2016 3.05 3.08 2.72 2.90 2.90 766,600
Oct 12, 2016 3.18 3.33 2.91 2.98 2.98 3,035,900
Oct 11, 2016 2.65 2.83 2.54 2.83 2.83 1,252,000
Oct 10, 2016 2.80 3.14 2.76 2.84 2.84 7,504,200
Oct 07, 2016 2.29 2.40 2.22 2.38 2.38 424,100
Oct 06, 2016 2.21 2.33 2.12 2.24 2.24 253,000
Oct 05, 2016 2.17 2.19 2.10 2.19 2.19 107,700
Oct 04, 2016 2.35 2.40 2.11 2.14 2.14 441,800
Oct 03, 2016 2.14 2.36 2.08 2.25 2.25 587,800
Sep 30, 2016 2.05 2.10 2.00 2.10 2.10 190,400
Sep 29, 2016 2.03 2.06 1.98 2.00 2.00 127,300
Sep 28, 2016 2.12 2.12 1.89 2.03 2.03 467,500
Sep 27, 2016 2.23 2.23 2.02 2.09 2.09 220,400
Sep 26, 2016 2.06 2.25 2.05 2.21 2.21 342,600
Sep 23, 2016 2.00 2.24 2.00 2.11 2.11 1,012,800
Sep 22, 2016 1.85 2.34 1.83 2.30 2.30 1,521,100
On Oct, 7, 2016, IPCI "received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths."
http://www.intellipharmaceutics.com/releasedetail.cfm?ReleaseID=992728
On Oct, 13, 2016, IPCI's 3Q came out and it was a miss and the stock slid, only to come back into the $3 range for a few days near the time of the NDA app. for Rexista was submitted (Nov 25). Let's hope for the $3 range and more next time. I doubt it will last once the shorts get back into business.
Perhaps, this change was for their benefit? I'm not sure if there are SEC codes of conduct or guidelines these investor services have to follow when they suggest a price target, or a buy, sell, hold, etc. on a particular stock. Perhaps, they were hoping for a major drop in order to buy up shares, while saying "Suckers" to those nervous nellies. I guess you can take this lowered price target by Aegis as a SELL? Zacks seems to waiver on IPCI, one week it's a BUY, and just a couple days later it's a HOLD or a SELL. What say you?
I hope someone does not come around and say he's going to pop this thing believing that it will run.
Nice indeed. Let's hope this time it continues the uptrend until the awaited announcement.
Let's get this oil thing going.
May something big happen soon.
Mallinckrodt has been doing quite well recently. It has received a couple of buy ratings and price targets are at $70 to $100. I would love to see a buyout in the coming months.
https://www.thecerbatgem.com/2017/04/25/jefferies-group-llc-reiterates-buy-rating-for-mallinckrodt-plc-mnk.html
So, the shorts are in control until an announcement is made. I thought we'd get a slow increase each day, but I was wrong on that. I guess the shorts know that they have upper hand in controlling this stock because of the fear factor. Either it goes up nicely a day or two before May 1st, or it remains sluggish; moreover, I'm sure this stock price target from Aegis and their HOLD recommendation has some worried. I'm not. Even Zacks has a BUY still, which as we all know could change any day now knowing that they have folks who probably work to short this stock IMO.
A half billion to opioid epidemic, and another half billion next year.
"The federal government will provide states nearly half a billion dollars for prevention and treatment programs aimed at confronting the opioid epidemic," and "another half-billion dollars in state grants will follow next year." ...."The grants are targeted at training for health professionals, technology and support for prescription drug monitoring programs that aim to prevent abuse and identify patients who may need help. Price said the grants also can be used to promote the use of overdose-reducing drugs such as naloxone."
https://www.google.com/amp/www.nbcnews.com/storyline/americas-heroin-epidemic/amp/trums-admin-pay-cash-promised-obama-fight-opioid-crisis-n748671
Love to see a breakout today.
Someone is playing games.
Slow accumulation to begin til May 1St.
Forbes: "Four Cancer-Killing Viruses To Watch In 2017" (Note: I found the link to this story from Oncorus' website, the previously mentioned privately held company that Celgene helped fund)
Oncolytics gets some air time. I'm sure this story was posted here on this message board last year:
"Reovirus: Canada-based Oncolytics Biotech is in phase 2 trials of its reovirus-based drug, Reolysin, in several tumor types, including breast, prostate and pancreatic cancer. It has also initiated several combination trials of the compound, which is a proprietary version of a virus that in its natural form causes respiratory illnesses. The development path has been plagued with disappointments, though, causing the company’s stock to plummet and ultimately leading to the departure of CEO Brad Thompson.
But the company is pressing on, announcing recently a new trial of Reolysin in combination with Keytruda in pancreatic cancer.
And other research groups have taken an interest in the cough virus and its potential to combat cancer, too. In November, a group of London-based scientists announced that in mouse studies, reovirus seems to kill both liver cancer and hepatitis C, which is the virus that commonly causes liver cancer. They’re now planning trials in people—adding yet another research program to keep an eye on as the oncolytic virus field continues to develop."
https://www.forbes.com/sites/arleneweintraub/2016/12/29/four-cancer-killing-viruses-to-watch-in-2017/#342917bc65cc